Déjà Vu: EGF Receptors Drive Resistance to BRAF Inhibitors

Maria Romina Girotti and Richard Marais

Summary: The promise of personalized medicine is upon us, and in some cancers, targeted therapies are rapidly becoming the mainstay of treatment for selected patients based on their molecular profile. The protein kinase BRAF is a driver oncogene in both thyroid cancer and melanoma, but while drugs that target BRAF and its downstream signaling pathway are effective in melanoma, they are ineffective in thyroid cancer. In this issue of Cancer Discovery, Montero-Conde and colleagues investigate why thyroid cancer is resistant to BRAF inhibitors despite the presence of BRAF mutation. Cancer Discov; 3(5); 487-90. ©2013 AARC.

See related article by Montero-Conde et al., p. 520 (9).

In 2002 (1), the first cancer genome resequencing study was published. It reported that the BRAF gene is mutated in approximately 7% of human cancers, and it took less than a decade for this seminal discovery to impact the clinical management of human cancer. There are 3 RAF genes in humans (ARAF, BRAF, and CRAF), and they encode protein kinases that are components of a signaling pathway activated downstream of receptor tyrosine kinases (RTK) and the small G-protein RAS (Fig. 1A). RAF proteins activate MAP-ERK kinase (MEK), which then activates extracellular-regulated kinase (ERK) to regulate cell growth and survival (Fig. 1A). BRAF mutations are common in melanoma (~50%), colorectal cancer (~15%), and papillary thyroid cancer (~40%; http://cancer.sanger.ac.uk/cosmic/), and this discovery led to rapid increases in our understanding of the molecular mechanisms underlying tumorigenesis in those cancers and ignited a hunt for a BRAF-targeting drug. This investment paid off 2 years ago when vemurafenib (PLX4032/RG7204) was approved for treatment of BRAF-mutant melanoma by the U.S. Food and Drug Administration, receiving Canadian and European licenses a few months later.

Vemurafenib is a potent and selective BRAF inhibitor that increases progression-free and overall survival in approximately 80% of patients with melanoma whose tumors carry BRAF mutations (2, 3). In its wake are several equally promising BRAF drugs, such as dabrafenib (4), and several MEK inhibitors, such as trametinib (5) and selumetinib (6), which are also active in these patients. Thus, following advances in chronic myeloid leukemia, gastrointestinal stromal tumors, and lung cancer, BRAF and MEK inhibitors have made personalized medicine a reality for patients with melanoma and changed the perception that this disease is essentially untreatable.

Curiously, despite the remarkable responses to BRAF/MEK inhibitors in melanoma, the response of other BRAF-driven cancers to these drugs is very disappointing. Only approximately 5% of BRAF-mutant colorectal patients respond to vemurafenib (7), and thyroid cancers do not respond to selumetinib (8). In this issue of Cancer Discovery, Montero-Conde and colleagues (9) investigate the reasons underlying the intrinsic resistance of BRAF-mutant thyroid cancer cells to BRAF inhibitors. They show that while BRAF and MEK inhibitors induce sustained ERK inhibition in BRAF-mutant melanoma cells, they induce only transient ERK inhibition in BRAF-mutant thyroid cancer cells and that the rapid rebound in signaling is due to increased HER3, a member of the EGF receptor family. HER3 activation appears to be part of a generalized hyperactivation of RTKs, but it is HER3 together with the closely related HER2 that reactivates RAS-ERK signaling and allows the cells to bypass the growth-inhibitory effects of BRAF inhibition (Fig. 1B). Notably, vemurafenib increases neuregulin-1 (NRG1) (the HER3 ligand) production. Intriguingly, the authors also found that oncogenic BRAF normally blocks HER3 expression through the transcriptional repressors C-terminal binding protein 1 and 2 (CTBP1/2), so BRAF inhibition increases HER3 expression (Fig. 1B). Thus, they have revealed the release of a feedback loop from oncogenic BRAF to HER3 and a general call to arms by this pathway that releases the cells’ addiction to oncogenic BRAF when BRAF is inhibited.

This all sounds curiously familiar. Last year, it was shown that colorectal cells are also insensitive to vemurafenib because of elevated HER1 (EGF receptor) signaling (10, 11). Here, again, vemurafenib only induced transient ERK inhibition with the rebound being driven by HER1, which signaled through RAS to AKT (10, 11). In elegant experiments, it was also shown that in colorectal cells, oncogenic BRAF drives expression of CDC25C, a phosphatase that negatively regulates HER1 (11). Thus, when BRAF was inhibited, CDC25C expression was lost, leading to HER1 activation. Thus, although the molecular details differ in both thyroid and colorectal cancers, BRAF inhibitors release a feedback loop that activates intrinsic resistance against themselves (Fig. 1B).

Increased RTK signaling also mediates acquired resistance to BRAF inhibitors in melanoma cells. A disappointment with BRAF and MEK drugs is that despite remarkable...
Figure 1. Mechanisms of resistance to BRAF inhibitors. A, gray rectangle: mutant BRAF (BRAF\textsuperscript{V600E}) hyperactivates ERK signaling and promotes tumor cell proliferation and survival, but BRAF and MEK drugs inhibit the pathway and block tumor progression. Main figure: resistance to BRAF inhibitors is mediated by several mechanisms, including expression of a truncated form of mutant BRAF, increased expression of mutant BRAF or wild-type CRAF, acquisition of mutations in RAS or MEK, expression of MAP3K8/COT, loss of PTEN expression, activation of the receptor tyrosine kinases PDGFR\(\beta\), IGF-IR, HER1, and HER2/HER3, or increased activation of MET through the increased secretion of hepatocyte growth factor (HGF) by the stromal compartment. (continued on following page)

initial responses, most patients with melanoma develop resistance after a relatively short period of disease control, (2–6) and, even when combined, most patients relapse after just over a year (12). Furthermore, about 20% of patients present with intrinsic resistance. Resistance can be driven by amplification of the mutant BRAF gene, expression of truncated mutant protein, acquisition of mutations in RAS and MEK, or hyperactivation of the PI3K/PTEN/AKT signaling pathway (Fig. 1A). Another common mechanism appears to be increased RTK signaling, with the PDGFR receptor, the insulin-like growth factor I receptor (IGF-IR), and MET all implicated (Fig. 1A). More important in this context, HER1 can also drive acquired resistance (13, 14). As in thyroid cancer, the underlying mechanism appears to be a general call to arms of signaling, with increased autocrine signaling by EGF, upregulation of HER1, and downregulation of the negative signaling regulator MIG6 (13, 14).

The parallels between the different diseases are intriguing, with similar general responses driven by distinct underlying mechanisms. Some of the details in thyroid cancer still need to be worked out. It is curious that HER3-mediated reactivation of ERK does not resuppress its own transcription through CTBP1/2, and it is unclear whether, as in colorectal cancer (10), CRAF rather than BRAF drives pathway reactivation. Nevertheless, the general theme that emerges is that high-content genomics and proteomics allow rapid understanding of mechanisms of resistance to targeted therapies. Genomics provides the clues, but it is the protein data that reveals the mechanisms. These studies provide biomarkers that can be used to screen patients for evidence of likely intrinsic resistance or to monitor patients in longitudinal studies for evidence of the emergence of resistance. Critically, in all of the cases discussed above, the combination of BRAF and EGF receptor family inhibitors suppressed the growth of the resistant cells, giving hope that effective personalized treatments can be developed for patients with intrinsic or acquired resistance.
**Disclosure of Potential Conflicts of Interest**

R. Marais has received honoraria from the Roche Speakers Bureau; is a consultant/advisory board member of Servier and GSK; and has given expert testimony for The Institute of Cancer Research. As a former employee of The Institute of Cancer Research, R. Marais also participates in a "Rewards to Inventors Scheme," which could provide financial benefits for contributions to programs that are commercialized. No potential conflicts of interest were disclosed by the other author.

**Grant Support**

R. Marais is supported by 2 grants from Cancer Research UK (C107/A10433 and C3579/A12328).

Published online May 8, 2013.

**REFERENCES**


Déjà Vu: EGF Receptors Drive Resistance to BRAF Inhibitors

Maria Romina Girotti and Richard Marais


Updated version
Access the most recent version of this article at:
http://cancerdiscovery.aacrjournals.org/content/3/5/487

Cited articles
This article cites 14 articles, 6 of which you can access for free at:
http://cancerdiscovery.aacrjournals.org/content/3/5/487.full#ref-list-1

Citing articles
This article has been cited by 3 HighWire-hosted articles. Access the articles at:
http://cancerdiscovery.aacrjournals.org/content/3/5/487.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.